Next week, the Pittsburgh Health Data Alliance (PHDA)—a collaboration among the University of Pittsburgh Medical Center (UPMC) , the University of Pittsburgh and Carnegie Mellon University that is focused on building new companies that create data-intensive software and services focused on healthcare and wellness—will host an event, “The Next Big (Data) Thing,” which will cover the role of Pittsburgh’s universities, leading health systems, and the tech industry in creating value from data.
As the Pittsburgh Health Data Alliance (PHDA) enters its third year, researchers, scientists, clinicians and executives from these organizations will get together to discuss the progress and promise of the PHDA in creating data-focused solutions to some of the biggest challenges in healthcare. Indeed, announced in March 2015, this alliance aims to leverage massive amounts of data—from electronic health records (EHRs), imaging, prescriptions, genomics, insurance records and wearable devices—to improve healthcare and wellness. Rob Hartman, program manager, UPMC Enterprises (the venture arm of UPMC), and who oversees the relationship within the Pittsburgh Health Data Alliance, recently spoke with Healthcare Informatics about what the alliance is working on, what have been the biggest lessons learned in the past few years, and what’s on the docket for the next year. Below are excerpts of that interview.
As the alliance enters its third year, what are some of the core lessons that have been learned?
In this alliance, UPMC funds early-stage research projects and commercially-oriented research projects at both universities [CMU and University of Pittsburgh], and we provide not only the funding for this research, but also access to clinicians, the living lab to UPMC, access to healthcare data, and commercialization advice for the healthcare sector so we can steer projects to high-impact targets in healthcare.
One primary lesson we have learned is that UPMC needs to engage early on in the process and be prescriptive about what our priorities are in healthcare so that we can help the investigators who are working on world-class technologies, help point companies to high-value and high-impact priorities and opportunities in healthcare. The secondary lesson is that we have created the right organizational and data governance structures to facilitate the speed at which proposals are sourced, evaluated and then managed and selected.
What projects are the alliance working on now?
As a reminder, the work is with researchers that are in pre-company formation in the PHDA, so these are teams of investigators that hopefully will become companies. Some of the priorities we have, not just in UPMC, but that are shared in healthcare, are making precision medicine tangible or real; providing consumer-focused care, so how we can construct models for healthcare that put the consumer or patient at the center of care; also, telehealth is very important; and behavioral medicine is too, so understanding how lifestyle behaviors contribute to health, wellness, and disease. These are the broader areas.
In the precision medicine [bucket], we have a couple of technologies that we have funded the development of to help bring precision medicine out of the cloud and down to earth. The big vision for precision medicine is being able to provide personalized treatment, so understanding the characteristics or features of an individual and [then] prescribe certain treatments that would be effective for that individual. So how do you do that? One of the key pieces you need is individualized diagnostics so you understand what’s going on in that person.
One area we are focusing on in the alliance is precision medicine in oncology, and one such project we funded is tumor driver identification. This means taking the genetic information from an individual tumor and using casual inference modeling to provide an interpretation of that genetic and other data to interpret the biological changes and mutations in that tumor to identify which genetic mutations are actually driving that individual tumor. Most precision medicine approaches that analyze the genetic sequence are general and population-based. But this approach is providing individualized genetic interpretation, so for a patient’s tumor, which genetic alterations are driving that tumor? So it allows you to then prescribe a therapy to address the underlying cause of that particular tumor.
Overall, what are the biggest challenges in creating these data-focused solutions?
Getting access to the data you need on the right scale is challenging, but that also points to a strength of the PHDA, in that we are helping the researchers get that data. Data access is quite important from the researcher’s perspective, and then also matching that data with clinical outcomes is important too, and that speaks to the strength of the PHDA as well, where we can provide the data and match that up with the progression or how that patient did or is doing.
Get the latest information on Health IT and attend other valuable sessions at this two-day Summit providing healthcare leaders with educational content, insightful debate and dialogue on the future of healthcare and technology.